Professor Isabel Rozas

Isabel Rozas was born in Madrid (Spain). After completing her BSc (honours) in Chemistry at the Universidad Complutense de Madrid in 1981, and her "Licenciado de grado" degree (similar to a MSc) in 1982, her PhD research was embarked upon at the Instituto de Quimica Medica in the National Council of Research (CSIC) in Madrid, and the degree achieved in 1987 at the Universidad Complutense de Madrid. Thereafter, she worked as a postdoctoral researcher at both the Department of Chemistry of the University of Saskatchewan (Canada) between 1989 and 1990, and the Department of Chemistry of Queen's University in Kingston (Canada) between 1993 and 1994. She worked as a researcher in the Medicinal Chemistry Institute (CSIC) until the year 2000, thereafter joining the School of Chemistry in TCD as a Lecturer. After being promoted to Senior Lecturer, and becoming a Fellow of TCD (2005), she became Associate Professor (later named Professor in) in 2011. She has supervised 19 PhD students and 5 MSc, earned approximately 2,500,000 EUR in research income and published 168 peer-reviewed research outcomes. During 2009-2012 she served as External Examiner in Organic/Medicinal Chemistry at the School of Chemistry in NUI Maynooth and during 2012-2016 in the Department of Chemistry and Pharmaceutical Chemistry (serving the Schools of Pharmacy and Medicine) at the Royal College of Surgeons in Ireland. Additionally, she has held positions as Director of the Medicinal Chemistry Moderatorship, member of the Fellowship Central committee, Head of Organic, Medicinal and Biological Chemistry at the School of Chemistry, Director of Postgraduate Teaching and Learning, Director of Research and Director of Global Relationships at the School of Chemistry, Director of Dublin Chemistry postgraduate program, Tutor and served in numerous College committees and selection panels. Moreover, she has served in different scientific committees such as the Irish panel of the ERA-Chemistry panel, the Irish Centre of High-End Computing or the XXIII EFMC-International Symposium in Medicinal Chemistry held in Lisbon in September 2014, and the WATOC Theoretical Chemist conference to be held in Vancouver 2022. Additionally, she has organised the first Medicinal Chemistry Ireland conference in 2016 (TCD, Dublin) and co-organised the second and third editions (DCU-2018, NUI-Galway-2022); besides, she has driven the foundation of the Division of Medicinal and Biological Chemistry within the Institute of Chemistry of Ireland (ICI) and its adherence to the European Federation of Medicinal Chemistry and Chemical Biology (EFMC) in 2022. Between 2019 and 2022 she has been an Editor of the journal Bioorganic and Medicinal Chemistry Letters (Elsevier).

  Anticancer therapies   Chemistry of drug receptor interactions   Computational Biology   Computational chemistry and modelling   Computer assisted drug design   Depression   Design and synthesis of drugs   Drug development and evaluation   Drug discovery   Genitourinary, prostatic function and disease   Hetrocyclic chemistry   Hydrogen bonding   Malaria   Medicinal Chemistry   Molecular Biology   Neurodegeneration   Organic chemistry   Protein chemistry, structure and folding   Quantum chemistry   Structural Biology, Determination, Function   Synthesis and new molecules   Theoretical chemistry

Research forms the core of my work and I am considered an international leader in Medicinal Chemistry. My work is published in highly prestigious international journals and my expert opinion sought from several sources, attesting to my expertise in the area. More importantly, my transformational impact and leadership has been acknowledged with increasing citations (>455 in 2021). I have published 11 articles in the top-journal in my field (Journal of Medicinal Chemistry) and my citations clearly indicate a track-record of sustained achievement. Presently, my research is more productive than ever, with new ideas highlighting a continuing trajectory of research excellence and impact. This is reflected in recently obtaining major SFI funding to develop potential therapies for Covid-19. My aim is to find new therapies to cure diseases such as cancer, infections and neurological conditions. I am a dynamic researcher who combines experiment and computation, which makes my group unique. This multi-faceted nature of my research underlines my novel contributions. Current research includes: Computational Chemistry- Modelling drug-target interactions to evaluate in-silico new therapeutics; Computational study of weak interactions to understand biological activities or mechanisms of reaction. Experimental Medicinal Chemistry- synthesis and biochemical/pharmacological/biophysical evaluation of: Antagonists of alpha2-adrenoceptors as antidepressants/antipsychotics. This work has been mostly published in the top-journal in the field and rendered a patent application; Nucleic acids' ligands. We have prepared many derivatives targeting DNA as minor-groove binders (MGBs) with potential as anticancer, antimicrobial or antiparasitic agents. My expertise in the field of MGBs is internationally recognized. Now, we are developing fluorescent probes to bind guanine quadruplexes (GQs), that will enable to explore the GQs' role in human diseases (cancer, ALS); Protein kinases inhibitors. Different families of novel derivatives are being prepared as inhibitors of the kinases BRAF or JAK2 showing excellent results in treating a particular cancer, Multiple Myeloma; Anti-tuberculosis therapies. We are developing inhibitors of the enzyme InhA, which is key in the biosynthesis of the cellular wall of the tuberculosis pathogen. Our compounds are showing an anti-mycobacterial activity similar to that of current therapies. Recently, we have started exciting research involving the development of inhibitors of the TMPRSS2 protease that activates the protein spike of the SARS-CoV-2 virus (responsible of the COVID19 pandemic); by blocking this protease our potential antiviral agents will stop the entrance of the virus into lung cells. My emphasis is on producing innovative research disseminated in high-ranking international journals and translated into biologically active compounds. Since becoming Professor, I have published 64 high-ranking international peer-reviewed publications (168 publications in total, plus 2 submitted). The significance of my research can be judged by the journals where I publish (e.g. Medicinal Research Reviews, IF:12.944; Journal of Medicinal Chemistry, IF:7.446; Chemical Society Reviews, IF:54.56 or Journal of the American Chemical Society, IF:15.42) and by the recognition of the results presented. In terms of citations (WoS) while the average citation/article in Medicinal-Chemistry is 29.15, the average citation for each of my 169 publications is 40.36. All these indicators positively compare with international Full-Professors in the field.